NVS phase-3 for Ilaris in NSCLC misses OS primary endpoint: https://www.globenewswire.com/news-release/2021/03/09/2189145/0/en/Novartis-provides-update-on-Phase-III-study-evaluating-canakinumab-ACZ885-as-second-or-third-line-treatment-in-combination-with-chemotherapy-in-non-small-cell-lung-cancer.html